Ascentage hopes to become a new force in BTK.
ApexOnco Front Page
Recent articles
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
But, like Merck two weeks ago, GSK has failed to hit overall survival.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
